Selpercatinib (RETEVMOTM) and pralsetinib (GAVRETOTM) are highly selective RET inhibitors designed to overcome the gatekeeper mutations20,21 and approved by the FDA in 2020 for RET-mutant thyroid and lung cancers22–24. Here, RET is linked to thyroid gland disorder.